| Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial SR Targan, BG Feagan, RN Fedorak, BA Lashner, R Panaccione, ... Gastroenterology 132 (5), 1672-1683, 2007 | 683 | 2007 |
| Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis P Lepage, R Häsler, ME Spehlmann, A Rehman, A Zvirbliene, A Begun, ... Gastroenterology 141 (1), 227-236, 2011 | 674 | 2011 |
| Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study ME Spehlmann, AZ Begun, J Burghardt, P Lepage, A Raedler, ... Inflammatory bowel diseases 14 (7), 968-976, 2008 | 293 | 2008 |
| Heart failure is associated with depletion of core intestinal microbiota M Luedde, T Winkler, FA Heinsen, MC Rühlemann, ME Spehlmann, ... ESC heart failure 4 (3), 282-290, 2017 | 244 | 2017 |
| Absence of RNase H2 triggers generation of immunogenic micronuclei removed by autophagy K Bartsch, K Knittler, C Borowski, S Rudnik, M Damme, K Aden, ... Human molecular genetics 26 (20), 3960-3972, 2017 | 206 | 2017 |
| IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens SM Dann, ME Spehlmann, DC Hammond, M Iimura, K Hase, LJ Choi, ... The Journal of Immunology 180 (10), 6816-6826, 2008 | 206 | 2008 |
| Nuclear factor-kappa B in intestinal protection and destruction ME Spehlmann, L Eckmann Current opinion in gastroenterology 25 (2), 92-99, 2009 | 190 | 2009 |
| Constitutive intestinal NF-κB does not trigger destructive inflammation unless accompanied by MAPK activation M Guma, D Stepniak, H Shaked, ME Spehlmann, S Shenouda, ... Journal of Experimental Medicine 208 (9), 1889-1900, 2011 | 178 | 2011 |
| Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab WJ Sandborn, MT Abreu, G D'Haens, JF Colombel, S Vermeire, K Mitchev, ... Clinical Gastroenterology and Hepatology 8 (8), 688-695. e2, 2010 | 178 | 2010 |
| A functional methylome map of ulcerative colitis R Häsler, Z Feng, L Bäckdahl, ME Spehlmann, A Franke, A Teschendorff, ... Genome research 22 (11), 2130-2137, 2012 | 149 | 2012 |
| CXCR2-dependent mucosal neutrophil influx protects against colitis-associated diarrhea caused by an attaching/effacing lesion-forming bacterial pathogen ME Spehlmann, SM Dann, P Hruz, E Hanson, DF McCole, L Eckmann The Journal of Immunology 183 (5), 3332-3343, 2009 | 112 | 2009 |
| International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the … SR Targan, BG Feagan, RN Fedorak, BA Lashner, R Panaccione, ... Gastroenterology 132 (5), 1672-1683, 2007 | 93 | 2007 |
| Interferon-β-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial E Musch, T Andus, W Kruis, A Raedler, M Spehlmann, S Schreiber, ... Clinical Gastroenterology and Hepatology 3 (6), 581-586, 2005 | 81 | 2005 |
| Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer J Bauer, O Ozden, N Akagi, T Carroll, DR Principe, JJ Staudacher, ... Molecular cancer 14, 1-14, 2015 | 67 | 2015 |
| Risk factors in German twins with inflammatory bowel disease: results of a questionnaire-based survey ME Spehlmann, AZ Begun, E Saroglou, F Hinrichs, U Tiemann, A Raedler, ... Journal of Crohn's and Colitis 6 (1), 29-42, 2012 | 57 | 2012 |
| Whole genome and exome sequencing of monozygotic twins discordant for Crohn’s disease BS Petersen, ME Spehlmann, A Raedler, B Stade, I Thomsen, R Rabionet, ... BMC genomics 15, 1-11, 2014 | 49 | 2014 |
| Trp53 deficiency protects against acute intestinal inflammation ME Spehlmann, CF Manthey, SM Dann, E Hanson, SS Sandhu, LY Liu, ... The Journal of Immunology 191 (2), 837-847, 2013 | 37 | 2013 |
| Radial access protects from contrast media induced nephropathy after cardiac catheterization procedures T Feldkamp, M Luedemann, ME Spehlmann, S Freitag-Wolf, ... Clinical Research in Cardiology 107, 148-157, 2018 | 36 | 2018 |
| Combined α-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease A Marx, T Wandrey, P Simon, A Wewer, T Grob, U Reichelt, S Minner, ... Human pathology 40 (2), 166-173, 2009 | 31 | 2009 |
| Cardio-toxicity of checkpoint inhibitors OJ Müller, ME Spehlmann, N Frey Journal of Thoracic Disease 10 (Suppl 35), S4400, 2018 | 23 | 2018 |
